NCT00504101撤回1 期
Phase I Clinical Trial of Dose Escalated Bortezomib + ATO (Arsenic Trioxide) + Melphalan as a Conditioning Regimen for Multiple Myeloma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Evaluate toxicity of the conditioning treatment regimen.
研究概览
简要总结
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as arsenic trioxide and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving high-dose combination chemotherapy together with bortezomib may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with arsenic trioxide and melphalan in treating patients undergoing an autologous stem cell transplant for multiple myeloma.
详细描述
OBJECTIVES:
Primary
- Evaluate toxicity of a conditioning treatment regimen comprising bortezomib, arsenic trioxide, and melphalan.
Secondary
- Evaluate response and overall survival.
- Determine what correlative laboratory and clinical parameters, if any, are associated with efficacy (e.g., serum arsenic trioxide intracellular glutathione depletion, gene profiling of myeloma cells).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Inclusion criteria:
- •Confirmed diagnosis of multiple myeloma (M-protein by serum protein electrophoresis or urine protein electrophoresis) and either bone marrow biopsy and aspirate demonstrating a plasma cell count > 10% or biopsy of a bone or soft tissue mass demonstrating a plasmacytoma
- •Demonstration of an indication for therapy based on symptoms (e.g., boney pain), hypercalcemia, anemia, renal insufficiency, symptomatic plasmacytomas, multiple boney lytic lesions, etc
- •Stable disease or has achieved a partial remission or complete remission to pre-transplant cyto-reductive therapy
- •Primary refractory disease (no response to therapy but stable) is permitted
- •Candidate for high-dose chemotherapy with autologous stem cell transplantation based on stabilization of disease with preparative chemotherapy (regardless of the specific agents)
- •A minimum of 2 x 10^6 CD34+ cells/kg must be collected prior to proceeding to transplant
排除标准
- •Evidence of active plasma cell leukemia
- •Relapsed refractory disease (patients who have achieved at least a partial response [PR] to previous therapy and are now refractory [have not achieved a PR to subsequent therapy])
- •Progressive disease on their last therapy
- •PATIENT CHARACTERISTICS:
- •Inclusion criteria:
- •Karnofsky performance status 60-100%
- •Creatinine < 3.0 mg/dL
- •AST and ALT <2.5 times upper limit of normal
- •Total bilirubin < 3 mg/dL
- •WBC ≥ 2,000/mm³
- •Platelet count ≥ 50,000/mm³
- •If abnormal hematologic function is attributable to bone marrow infiltration by multiple myeloma, the principal investigator will decide on a case-by-case basis if the patient's bone marrow reserve is appropriate for this study
- •Females of childbearing potential must have a negative serum pregnancy test prior to enrollment on the study and must use an effective barrier method while on the study
- •Ejection fraction > 40% and no history of uncontrolled ischemic heart disease or congestive heart failure
- •No evidence of cardiac amyloidosis by echocardiogram
- •DLCO and FEV_1 ≥ 50%
- •Exclusion criteria:
- •Active peripheral neuropathy ≥ grade 2
- •Recurrent supraventricular arrhythmia or any type of sustained ventricular arrhythmia or conduction block (e.g., A-V block grade II or III, left bundle branch block)
- •Known HIV infection
- •Pregnant or lactating women
- •Underlying medical condition that could be aggravated by the treatment or life-threatening disease unrelated to myeloma as evaluated by the enrolling physician
- •History of second malignancy within the past 3 years and not in complete remission from that malignancy, excluding adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or local prostate cancer
- •History of preexisting neurological disorders (grade 2 or higher by the NCI Common Toxicity Criteria, in particular seizure disorders)
- •PRIOR CONCURRENT THERAPY:
- •Inclusion criteria:
- •Previous radiation therapy for palliation of cord compression or pathologic fractures is permitted provided last dose is given 14 days prior to initiation of chemotherapy
- •Subjects with radiographic evidence of lytic bone disease receiving concomitant bisphosphonate therapy may be enrolled
- •Bisphosphonates should be held at least 1 week prior to the transplant but continuing bisphosphonates after day +60 is at the discretion of the treating physician
- •Exclusion criteria:
- •Previous autologous or allogeneic transplantation
- •Other investigational or experimental drug or therapy while on the study
结局指标
主要结局
Evaluate toxicity of the conditioning treatment regimen.
时间窗: 3 ¼ years
次要结局
- Evaluate response and overall survival (OS).(3 ¼ years)
- Determine what correlative laboratory and clinical parameters, if any, are associated with efficacy(3 ¼ years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple MyelomaAutologous Hematopoietic Stem Cell Transplant RecipientLoss of Chromosome 17pRecurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaPlasma Cell LeukemiaNCT01163357City of Hope Medical Center18
已完成
1 期
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myelomonocytic Leukemia (M4)Adult Pure Erythroid Leukemia (M6b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Erythroleukemia (M6a)NCT01127009Case Comprehensive Cancer Center3
已完成
1 期
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00028912Memorial Sloan Kettering Cancer Center
已完成
1 期
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsRefractory Plasma Cell MyelomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaSplenic Marginal Zone LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Grade 1 Follicular LymphomaNodal Marginal Zone LymphomaWaldenstrom MacroglobulinemiaNCT00082784National Cancer Institute (NCI)93
终止
1 期
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular LymphomaLymphomaNCT00372905Northwestern University18